Yeleswaram Krishnaswamy
Known title: Chief Development OfficerCIK: 0002022156
Associated companies
Transaction History
| RAPP | ▼ Sell | Open Market | 20,799 | $1.0M | 8/25/2026 | View on chart |
| RAPP | ▼ Sell | Open Market | 16,201 | $827K | 8/25/2026 | View on chart |
| RAPP | ▼ Sell | Open Market | 13,160 | $658K | 8/24/2026 | View on chart |
| RAPP | ▼ Sell | Open Market | 404 | $20K | 8/19/2026 | View on chart |
| RAPP | ▼ Sell | Open Market | 20,225 | $809K | 4/17/2026 | View on chart |
| RAPP | ▼ Sell | Open Market | 10,200 | $358K | 4/14/2026 | View on chart |
| RAPP | ▼ Sell | Open Market | 9,165 | $321K | 4/13/2026 | View on chart |
| RAPP | ▼ Sell | Open Market | 500 | $17K | 4/10/2026 | View on chart |
| RAPP | ▼ Sell | Open Market | 360 | $13K | 4/8/2026 | View on chart |
| RAPP | ▼ Sell | Open Market | 10,115 | $303K | 3/25/2026 | View on chart |
| RAPP | ▼ Sell | Open Market | 2,840 | $85K | 12/31/2025 | View on chart |
| RAPP | ▲ Buy | Grant | 9,000 | — | 12/31/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Guggenheim initiates coverage of Rapport Therapeutics, sets $65 target
Guggenheim began coverage of Rapport Therapeutics and assigned a price target of $65. The target sits above the company's 52‑week high of $52.93, indicating a positive outlook. The stock currently trades with a low RSI and near a strong support level, which may influence market reaction to the new estimate.
Guggenheim initiates coverage of Rapport Therapeutics, sets $65 target. Guggenheim began coverage of Rapport Therapeutics and assigned a price target of $65. The target sits above the company's 52‑week high of $52.93, indicating a positive outlook. The stock currently trades with a low RSI and near a strong support level, which may influence market reaction to the new estimate.